Dr. Khaled Abdul-nour, M.D.
Cardiology (Cardiovascular Disease Physician)
Henry Ford Health System, 2799 West Grand Boulevard
Detroit, MI 48202
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,257
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MI license 4301059763 -
Internal Medicine Physician
MI license 4301059763
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health Hospital Detroit, MI
- Henry Ford Health West Bloomfield Hospital W Bloomfield, MI
- Henry Ford Allegiance Health Jackson, MI
- Wyandotte Hospital and Medical Center Wyandotte, MI
- Sinai-Grace Hospital Detroit, MI
Medical groups
- Henry Ford Health System (2,570 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,257
- Services billed
- 1,851
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 820 | 661 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 201 | 200 |
| Established patient office or other outpatient visit, 30-39 minutes | 68 | 59 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 39 | 22 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 35 | 35 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 32 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 33 | 33 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 32 | 32 |
| Nuclear medicine study of heart muscle blood flow by pet | 32 | 32 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 29 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $338,851 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]
Novartis Pharmaceuticals Corporation - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Amgen Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascula…
Novartis Pharmaceuticals Corporation - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.